|
시장보고서
상품코드
1941244
혈소판 응집 장치 시장 보고서 : 제품별, 유형별, 용도별, 최종사용자별, 지역별(2026-2034년)Platelet Aggregation Devices Market Report by Product, Type, Application, End User, and Region 2026-2034 |
||||||
세계의 혈소판 응집 장치 시장 규모는 2025년에 6억 1,350만 달러에 이르렀습니다. 향후, IMARC Group은 2026-2034년 CAGR 4.68%를 나타내, 2034년까지 9억 3,760만 달러에 이를 것으로 예측했습니다.
혈소판 응집 기기에는 아데노신이인산(ADP), 트롬빈, 리포세틴 유도 혈소판 응집(RIPA)이 포함됩니다. 이 장치는 과다출혈, 동맥혈전증, 뇌졸중, 심근경색 등 유전성 및 후천성 혈소판 기능 장애가 있는 환자의 진단에 사용됩니다. 수혈, 수술 전 검사, 임상 현장에서 항혈소판 치료 반응을 모니터링하고 수술 전후 출혈 위험을 평가할 수 있도록 지원합니다. 현재, 새로운 잠재적 바이오마커와 기술의 도입으로 혈소판 응집 기기는 전 세계적으로 항혈소판제 맞춤형 치료 및 각종 지혈 요법의 효과 모니터링에 광범위하게 적용되고 있습니다.
혈소판 응집 기기 시장 동향 :
COVID19 진단을 받은 환자의 혈소판 응집 증가가 시장 성장을 견인하고 있습니다. 또한, 전 세계적으로 대장암, 심혈관 질환, 가와사키병, 급성관상동맥증후군(ACS), 급성 허혈성 뇌졸중, 급성 류마티스성 질환의 유병률이 증가함에 따라 출혈 위험이 증가하고 있습니다. 이는 혈소판 기능 장애의 임상 관리에서 혈소판 응집 기기 시장의 성장을 가속하는 또 다른 중요한 요인이 되고 있습니다. 또한, 만성질환을 앓고 있는 고령 인구의 현저한 증가도 시장 성장에 기여하고 있습니다. 이와 더불어, 주요 제조업체들은 제품 포트폴리오 확대와 시장에서의 경쟁 우위 유지를 위해 신제품을 속속 출시하고 있습니다. 또한, 보다 간편한 현장진단(POC, Point-of-Care) 진단기기 개발에도 주력하고 있습니다. 이 장비들은 유전성 및 후천성 출혈성 질환과 항혈소판 치료의 효과를 신속하게 평가할 수 있는 최신 연구 기법을 채택하고 있습니다. 이와 더불어, 방대한 인구의 의료 수요를 충족시키기 위한 POC 진단 장비에 대한 수요 증가가 결합되어 시장을 견인할 것으로 예측됩니다.
본 보고서에서 답변을 얻을 수 있는 주요 질문
- 2025년 세계 혈소판 응집 기기 시장 규모는 어느 정도였습니까?
- 2026년부터 2034년까지 세계 혈소판 응집 기기 시장의 예상 성장률은?
- 코로나19가 세계 혈소판 응집 기기 시장에 어떤 영향을 미쳤는가?
- 세계 혈소판 응집 기기 시장을 이끄는 주요 요인은?
- 세계 혈소판 응집 기기 시장의 제품별 시장 분석은 어떻게 이루어지고 있는가?
- 세계 혈소판 응집 기기 시장의 유형별 시장 분석은 어떻게 이루어지고 있는가?
- 세계 혈소판 응집 기기 시장의 용도별 시장 분석은 어떻게 이루어지고 있는가?
- 세계 혈소판 응집 기기 시장의 최종 사용자별 시장 분석은 어떻게 이루어지고 있는가?
- 세계 혈소판 응집 기기 시장의 주요 지역은 어디인가?
- 세계 혈소판 응집 기기 시장의 주요 기업 및 기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 서론
제5장 세계의 혈소판 응집 장치 시장
제6장 시장 분석 : 제품별
제7장 시장 분석 : 유형별
제8장 시장 분석 : 용도별
제9장 시장 분석 : 최종사용자별
제10장 시장 분석 : 지역별
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter의 Five Forces 분석
제14장 가격 분석
제15장 경쟁 구도
LSH 26.03.11The global platelet aggregation devices market size reached USD 613.5 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 937.6 Million by 2034, exhibiting a growth rate (CAGR) of 4.68% during 2026-2034.
Platelet aggregation devices comprise adenosine-diphosphate (ADP), thrombin, and ristocetin-induced platelet aggregation (RIPA). These devices are used to diagnose patients with inherited and acquired platelet function disorders, such as excessive bleeding, arterial thrombotic, stroke, and myocardial infarction. They assist in transfusing medicines, pre-surgery tests, and clinical settings to monitor the response of antiplatelet therapies and assess perioperative bleeding risk. At present, due to the launch of new potential biomarkers and technologies, platelet aggregation devices are finding extensive application in personalizing antiplatelet drugs and monitoring the efficacy of various types of pro-hemostatic therapies around the world.
Platelet Aggregation Devices Market Trends:
The rising instances of platelet aggregation among patients diagnosed with coronavirus disease (COVID-19) are strengthening the growth of the market. Moreover, due to the growing prevalence of colon cancer, cardiovascular diseases, Kawasaki condition, acute coronary syndrome (ACS), acute ischemic stroke, and acute rheumatic disorders across the globe, there is an increase in the risk of bleeding. This acts as another key factor impelling the growth of the platelet aggregation devices market for clinical management of platelet function disorders. In addition, a significant rise in the aging population suffering from chronic diseases is contributing to the market growth. Apart from this, leading manufacturers are launching novel products to expand their product portfolio and retain a competitive edge in the market. They are also focusing on developing new and simpler point-of-care (POC) diagnostic devices. These devices rely on the latest methodologies for helping in the rapid evaluation of inherited and acquired bleeding disorders and antiplatelet therapies. This, coupled with the increasing need for POC diagnostic devices to fulfill the healthcare demand of the large population, is projected to drive the market.
Key Market Segmentation:
Breakup by Product:
- Systems
- Reagents
- Consumables and Accessories
Breakup by Type:
- Four Channel
- Dual Channel
- Eight Channel
Breakup by Application:
- Clinical Applications
- Research Applications
- Cardiovascular Applications
- Orthopedic Applications
- Others
Breakup by End User:
- Hospitals
- Diagnostic Laboratories
- Research and Academic Institutes
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aggredyne Inc., Chrono-Log Corporation, F. Hoffmann-La Roche AG, Grifols S.A., Hart Biologicals Ltd., Helena Laboratories Corporation, LAbor BioMedical Technologies GmbH, Matis Medical Inc., Sentinel Ch. S.P.A., Siemens AG, Sienco Inc., Sysmex Corporation and WerfenLife SA.
Key Questions Answered in This Report
- 1.What was the size of the global platelet aggregation devices market in 2025?
- 2.What is the expected growth rate of the global platelet aggregation devices market during 2026-2034?
- 3.What has been the impact of COVID-19 on the global platelet aggregation devices market?
- 4.What are the key factors driving the global platelet aggregation devices market?
- 5.What is the breakup of the global platelet aggregation devices market based on the product?
- 6.What is the breakup of the global platelet aggregation devices market based on the type?
- 7.What is the breakup of the global platelet aggregation devices market based on the application?
- 8.What is the breakup of the global platelet aggregation devices market based on the end user?
- 9.What are the key regions in the global platelet aggregation devices market?
- 10.Who are the key players/companies in the global platelet aggregation devices market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Platelet Aggregation Devices Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Systems
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Reagents
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Consumables and Accessories
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Type
- 7.1 Four Channel
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Dual Channel
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Eight Channel
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Application
- 8.1 Clinical Applications
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Research Applications
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Cardiovascular Applications
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Orthopedic Applications
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Diagnostic Laboratories
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Research and Academic Institutes
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 9.4 Others
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Aggredyne Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.2 Chrono-Log Corporation
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.3 F. Hoffmann-La Roche AG
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 SWOT Analysis
- 15.3.4 Grifols S.A.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Hart Biologicals Ltd.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.6 Helena Laboratories Corporation
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.7 LAbor BioMedical Technologies GmbH
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 Matis Medical Inc.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.9 Sentinel Ch. S.P.A.
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.10 Siemens AG
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Sienco Inc.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.12 Sysmex Corporation
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
- 15.3.13 WerfenLife SA
- 15.3.13.1 Company Overview
- 15.3.13.2 Product Portfolio
- 15.3.1 Aggredyne Inc.
